Please use this identifier to cite or link to this item:
https://dipositint.ub.edu/dspace/handle/2445/32192
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Izquierdo, Conchita | - |
dc.contributor.author | Salleras i Sanmartí, Lluís | - |
dc.contributor.author | Domínguez García, Àngela | - |
dc.date.accessioned | 2012-10-04T11:26:15Z | - |
dc.date.available | 2012-10-04T11:26:15Z | - |
dc.date.issued | 2012 | - |
dc.identifier.uri | http://hdl.handle.net/2445/32192 | - |
dc.description | Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393 | - |
dc.description.abstract | Although bacteremic pneumococcal pneumonia is the most severe form of pneumonia, non-bacteremic forms are much more frequent. Laboratory methods for the diagnosis of nonbacteremic pneumococcal pneumonia have a low sensitivity and specificity, and therefore all-cause pneumonia has been proposed as a suitable outcome to evaluate vaccination effectiveness. This work reviews the epidemiology of community-acquired pneumonia (CAP) and evaluates the effectiveness of the 3-valent pneumococcal polysaccharide vaccine (PPV-23) in preventing CAP requiring hospitalization in people aged ≥65 years. We performed a case-control study in patients aged ≥65 years admitted through the emergency department who presented with clinical signs and symptoms compatible with pneumonia. We included 489 cases and 1,467 controls and it was obtained a vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that PPV-23 vaccination is effective and reduces hospital admissions due to pneumonia in the elderly, strengthening the rationale for vaccination programmes in this age group. | eng |
dc.format.extent | 19 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | eng |
dc.publisher | Transworld Research Network | - |
dc.relation.isformatof | Reproducció del capítol 5 del llibre publicat a: http://www.trnres.com/ebookcontents.php?id=131 | - |
dc.relation.ispartof | Recent Advances in Pharmaceutical Sciences II, 2012, Editor: Diego Muñoz-Torrero, Diego Haro and Joan Vallès, Chapter 5, p. 69-87. | - |
dc.rights | (c) Transworld Research Network , 2012 | - |
dc.source | Llibres / Capítols de llibre (Medicina) | - |
dc.subject.classification | Farmacologia | cat |
dc.subject.classification | Pneumònia adquirida a la comunitat | cat |
dc.subject.classification | Vacunes | cat |
dc.subject.other | Pharmacology | eng |
dc.subject.other | Community-acquired pneumonia | eng |
dc.subject.other | Vaccines | eng |
dc.title | Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia? | eng |
dc.type | info:eu-repo/semantics/bookPart | eng |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | eng |
Appears in Collections: | Llibres / Capítols de llibre (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
RAPS_II_Ch5.pdf | 431 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.